17 February 2017
Pfizer Saudi Limited recently signed an exclusive agreement with Tabuk Pharmaceuticals, one of the leading pharmaceutical companies in Saudi Arabia and the region.
The venture leverages the local manufacturing capabilities of Tabuk and global promotional capabilities of Pfizer Saudi Limited.
Under the agreement, Pfizer Saudi Limited will have exclusive rights to promote and distribute high value branded generics.
The deal will enhance the availability of important medicines in therapeutic areas, such as central nervous system (CNS), kidney dialysis/transplant and urology.
Pfizer Innovative Health Cluster Lead of Saudi Arabia, Dr. Alaa Gamal said: “Pfizer Saudi Limited is committed to bringing the best in medicines to Saudi patients and improving access and outcomes for treatment in a cost effective way in the above therapeutic areas.”
Dr. Hamad Al-Khamees, general manager of Tabuk Pharmaceuticals, said: “We are excited about this opportunity enabled by the quality of our technical operations. This contributes to further strengthening Saudi Arabia’s local manufacturing industry, and we look forward to more cooperation in the future with Pfizer.”
© Arab News 2017